Compare CPSH & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPSH | NRXS |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 78.9M |
| IPO Year | 1995 | 2023 |
| Metric | CPSH | NRXS |
|---|---|---|
| Price | $5.21 | $7.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.8M | 87.4K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.64 | 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | $16.41 | $172.91 |
| Revenue Next Year | $20.16 | $115.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $2.11 | $2.20 |
| 52 Week High | $14.39 | $9.33 |
| Indicator | CPSH | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 53.64 |
| Support Level | $4.61 | $6.92 |
| Resistance Level | $5.50 | $7.79 |
| Average True Range (ATR) | 0.68 | 0.37 |
| MACD | -0.21 | 0.06 |
| Stochastic Oscillator | 9.97 | 81.63 |
CPS Technologies Corp designs, manufactures, and sells high-performance material solutions for customers across various markets, including transportation, energy, automotive, electronics, telecommunications, aerospace, and defense. The company develops and applies proprietary expertise in metal matrix composites (MMCs), which are engineered materials combining metals and ceramics to achieve enhanced performance properties. It also provides baseplates and housings used in radar, satellite and avionics applications. The company provides lids and heat spreaders used with integrated circuits in Internet switches and routers. The majority of the company's revenue is derived from the sale of its products in the United States of America.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).